cell.com
EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function
Isshiki et al. demonstrate that EZH2 inhibitors re-activate immune synapse functions between B cell lymphomas and T cells, sensitizing lymphomas to T cell immunotherapies. EZH2 inhibition enhances killing activity by promoting T cell recruitment, prolonging binding and increasing contact surface with lymphoma cells, and prevents T cell exhaustion. This strategy is currently under clinical evaluation.